Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease. Alzheimer’s Disease, Drugs (Pharmaceuticals), Clinical Trials, Falsification of Data, Regulation and Deregulation of Industry, Decisions and Verdicts, Research, Securities and Commodities Violations, Cassava Sciences Inc, simufilam, your-feed-science NYT > Health
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.
